NASHUA, N.H., Jan. 13, 2020 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ:ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, today announced Nathaniel Dalton was appointed to its Board of Directors.

Mr. Dalton is one of the founders of the global asset management firm Affiliated Managers Group, Inc. (NYSE:AMG), where he remains a Director and Senior Advisor. Mr. Dalton held a range of executive positions at AMG, including General Counsel, Chief Operating Officer, President and Chief Executive Officer. He was also the founding investor of Talari Networks, the pioneering SD-WAN technology company, serving as a board observer for more than a decade; and is an investor in, and advisor to, several growth companies operating at the intersection of technology and healthcare. Mr. Dalton is a Trustee of Boston University and serves on the Investment Committee for its Endowment. He also serves on the Advisory Board of the Institute for Sustainable Energy. Mr. Dalton received a J.D. from Boston University School of Law and a B.A. from the University of Pennsylvania.

“We are very pleased to add Nate as a Director of our Company. We have had the opportunity to get to know each other since he first invested in iCAD over a year ago, and we are confident he will make significant contributions to the Company,” said Michael Klein, Chairman and CEO. “Not only does he have decades of experience in both capital markets and in building a significant public company, but he also brings a proven entrepreneurial approach and understanding of technology companies. We look forward to working with Nate as we capitalize on iCAD’s tremendous growth opportunities in both the cancer detection and therapy parts of our business to create significant value for patients, their caregivers and our shareholders.”

“I am very excited to work with the team at iCAD at this time of tremendous opportunity for the Company,” said Mr. Dalton. “iCAD and its platforms for cancer detection and cancer therapy have the potential to significantly improve outcomes for patients and enhance the effectiveness and cost-efficiency of healthcare services.”

About iCAD, Inc.

Headquartered in Nashua, NH, iCAD is a global medical technology leader providing innovative cancer detection and therapy solutions. For more information, visit www.icadmed.com.